Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9291)	10/11/2003 2:24:29 PM
From: BubbaFred	Read Replies (2) \| Respond to of 52153

Peter - I am looking at this one company and several recent news releases including a patent. Is the patent described in the following news release and from their website have merit or just hocus pocus? If the potential is high, I would expect larger pharmas would be knocking on their door to privide additional funding instead of a mere 1 Mil private financing. Appreciate getting your input. "The patent relates to the interaction of the mutative gene of enterotoxin A with the ScFv (Single-Chain Variable-Fragment) gene and the application of the fused protein in the immunotherapy for tumors." "Thrombreaker Drug - Thrombus-related diseases, wherein fibrous clots form in blood vessels or the heart, are some of the most common ailments in humans. According to the World Health Organization, 55% of the 52 million deaths in 1999 were from by noncontiguous diseases, mostly coronary heart disease and cerebral aploplexy caused by thrombosis. Eternal is developing a medicine, called Thrombreaker, that seeks to prevent thrombus-related diseases. Thrombreaker is based on adder antithrombin, the most effective type of thrombosis medication, and is manufactured through Eternal's revolutionary gene cloning techniques. The Company is the first in the world to successfully separate the coded genes of adder antithrombin." biz.yahoo.com eternalprc.com